CPRX - Catalyst Pharmaceuticals Inc

CPRX - Catalyst Pharmaceuticals Inc

https://catalystpharma.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Catalyst Pharmaceutical ( CPRX ) is a Top-Ranked Value Stock: Should You Buy?

Zacks Commentary • 2 hours, 3 minutes ago • score: 0.41

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks Commentary • 1 week, 5 days ago • score: 0.52

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Catalyst Pharmaceuticals President and CEO Trades $473K In Company Stock - Catalyst Pharmaceuticals ( NASDAQ:CPRX )

Benzinga • 2 weeks, 3 days ago • score: 0.28

Revealing a significant insider sell on August 28, Richard J Daly, President and CEO at Catalyst Pharmaceuticals CPRX, as per the latest SEC filing. What Happened: Daly's recent Form 4 filing with the U.S. Securities and Exchange Commission on Thursday unveiled the sale of 22,970 shares of ...

Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Value Stock

Zacks Commentary • 2 weeks, 3 days ago • score: 0.35

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire • 2 weeks, 4 days ago • score: 0.58

CORAL GABLES, Fla., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and ...

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - Catalyst Pharmaceuticals ( NASDAQ:CPRX )

Benzinga • 2 weeks, 4 days ago • score: 0.50

CORAL GABLES, Fla., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® ( amifampridine ) Patent Litigation with Lupin Pharmaceuticals - Catalyst Pharmaceuticals ( NASDAQ:CPRX )

Benzinga • 2 weeks, 5 days ago • score: 0.51

CORAL GABLES, Fla., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.

52W High

$26.58

52W Low

$19.00

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.85

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

12.30

Forward P/E (<15 better)

9.71

EV/EBITDA (<8 favorable)

6.52

EV/Revenue (<3 favorable)

3.28

P/S (TTM) (<3 favorable)

4.45

P/B (<3 favorable)

2.90

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

6.33%

Institutions (25–75% balanced)

85.49%

Shares Outstanding

122,391,000

Float

114,855,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

558,499,000

Gross Profit (TTM)

463,727,000

EPS (TTM)

1.65

Profit Margin (>10% good)

0.37%

Operating Margin (TTM) (higher better)

0.45%

ROE (TTM) (>15% strong)

0.29%

EPS YoY (Quarterly) (>10% good)

0.24

Revenue YoY (Quarterly) (>8% good)

0.19

Momentum

Bearish momentum

Value

-0.2615

Previous

-0.2646

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025